SCHEMBL2915065

SCHEMBL2915065

O=C(O)c1ccc2c(=O)n(-c3cc(O)ccn3)c(=S)[nH]c2c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.65
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ KMT2A Q03164 6/20 0.52
▸ ALDH1A1 P00352 9/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ HTT P42858 1/20 0.47
▸ DYRK1A Q13627 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ RAB9A P51151 1/20 0.43
▸ PARP1 P09874 1/20 0.43
▸ CSNK2A1 P68400 1/20 0.43
▸ KDM5A P29375 1/20 0.42
▸ KDM2B Q8NHM5 1/20 0.42
▸ KDM4C Q9H3R0 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2911602 0.87 KDM4E (0.70) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2903251 0.84 KDM4E (0.62) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2915423 0.83 KDM4E (0.71) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL3012410 0.81 KDM4E (0.64) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2910091 0.80 KMT2A (0.57) SMN1; SMN2KMT2AALDH1A1MEN1MAPT
SCHEMBL2903053 0.80 KMT2A (0.55) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2903097 0.79 KDM4E (0.65) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2900654 0.78 KDM4E (0.64) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL2919893 0.78 MEN1 (0.54) SMN1; SMN2KMT2AALDH1A1MEN1MAPT
SCHEMBL2915511 0.75 KDM4E (0.71) KDM4ESMN1; SMN2KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 KDM4E 206/4885SMN1; SMN2 4048/4885KMT2A 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback